EGFR and non-small cell lung carcinoma: EGFR (epidermal growth factor receptor) mutations or ALK (anaplastic lymphoma kinase) rearrangements in NSCLC usually exhibit poor clinical benefits to checkpoint inhibitor (CPI) [20,21], although few reports have explained the underlying mechanism.